Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
3.690
+0.140 (3.94%)
Nov 4, 2024, 4:00 PM EST - Market closed
Sutro Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
Cash & Equivalents | 90.79 | 69.27 | 47.25 | 30.41 | 206.15 | 4.96 | Upgrade
|
Short-Term Investments | 335.2 | 306.35 | 287.11 | 167.52 | 161.99 | 112.9 | Upgrade
|
Cash & Short-Term Investments | 425.99 | 375.62 | 334.36 | 197.94 | 368.14 | 117.86 | Upgrade
|
Cash Growth | 8.77% | 12.34% | 68.92% | -46.23% | 212.34% | -42.36% | Upgrade
|
Receivables | 6.95 | 36.08 | 7.12 | 12.45 | 5.56 | 6.3 | Upgrade
|
Prepaid Expenses | 10.53 | 9.85 | 11.67 | 8.12 | 4.49 | 4.41 | Upgrade
|
Total Current Assets | 443.48 | 421.54 | 353.15 | 218.52 | 378.18 | 128.57 | Upgrade
|
Property, Plant & Equipment | 39.75 | 44.76 | 51.06 | 51.59 | 12.94 | 9.63 | Upgrade
|
Long-Term Investments | - | - | - | 68.78 | - | 15.61 | Upgrade
|
Other Long-Term Assets | 5.82 | 4.44 | 2.73 | 2.53 | 2.99 | 2.56 | Upgrade
|
Total Assets | 489.04 | 470.74 | 406.94 | 341.41 | 394.11 | 156.37 | Upgrade
|
Accounts Payable | 6.09 | 9.44 | 4.8 | 6.01 | 5.54 | 5.58 | Upgrade
|
Accrued Expenses | 39.41 | 34.1 | 24.83 | 17.07 | 8.82 | 6.02 | Upgrade
|
Current Portion of Long-Term Debt | - | 4.06 | 12.5 | 9.38 | - | 1 | Upgrade
|
Current Portion of Leases | 6.93 | 6.42 | 4.59 | 1.04 | - | - | Upgrade
|
Current Income Taxes Payable | 0.01 | 15.17 | - | - | - | - | Upgrade
|
Current Unearned Revenue | 73.96 | 20.67 | 16.76 | 5.5 | 14.6 | 19.47 | Upgrade
|
Other Current Liabilities | 3.58 | 3.9 | 3.08 | 2.75 | 0.63 | 0.9 | Upgrade
|
Total Current Liabilities | 129.99 | 93.75 | 66.55 | 41.74 | 29.6 | 32.97 | Upgrade
|
Long-Term Debt | - | - | 3.77 | 15.74 | 24.55 | 8.88 | Upgrade
|
Long-Term Leases | 19.59 | 23.15 | 29.57 | 31.22 | - | - | Upgrade
|
Long-Term Unearned Revenue | 185.6 | 202.49 | 89.89 | - | 6.1 | 16.2 | Upgrade
|
Other Long-Term Liabilities | 1.69 | 1.69 | 0.12 | 0.15 | 1.82 | 0.54 | Upgrade
|
Total Liabilities | 336.87 | 321.09 | 189.9 | 88.84 | 62.06 | 58.58 | Upgrade
|
Common Stock | 0.08 | 0.06 | 0.06 | 0.05 | 0.05 | 0.02 | Upgrade
|
Additional Paid-In Capital | 817.9 | 708.98 | 670.22 | 586.24 | 559.75 | 293.35 | Upgrade
|
Retained Earnings | -665.64 | -559.41 | -452.62 | -333.41 | -227.87 | -195.75 | Upgrade
|
Comprehensive Income & Other | -0.16 | 0.02 | -0.62 | -0.31 | 0.13 | 0.17 | Upgrade
|
Total Common Equity | 152.18 | 149.65 | 217.05 | 252.56 | 332.05 | 97.79 | Upgrade
|
Shareholders' Equity | 152.18 | 149.65 | 217.05 | 252.56 | 332.05 | 97.79 | Upgrade
|
Total Liabilities & Equity | 489.04 | 470.74 | 406.94 | 341.41 | 394.11 | 156.37 | Upgrade
|
Total Debt | 26.53 | 33.64 | 50.43 | 57.37 | 24.55 | 9.88 | Upgrade
|
Net Cash (Debt) | 399.47 | 341.98 | 283.93 | 209.34 | 343.59 | 123.6 | Upgrade
|
Net Cash Growth | 14.47% | 20.44% | 35.63% | -39.07% | 177.99% | -34.87% | Upgrade
|
Net Cash Per Share | 6.05 | 5.68 | 5.60 | 4.54 | 10.55 | 5.38 | Upgrade
|
Filing Date Shares Outstanding | 81.96 | 62.44 | 60.16 | 46.38 | 45.89 | 23.1 | Upgrade
|
Total Common Shares Outstanding | 81.86 | 61.01 | 57.5 | 46.33 | 45.75 | 23.1 | Upgrade
|
Working Capital | 313.49 | 327.8 | 286.61 | 176.78 | 348.59 | 95.6 | Upgrade
|
Book Value Per Share | 1.86 | 2.45 | 3.77 | 5.45 | 7.26 | 4.23 | Upgrade
|
Tangible Book Value | 152.18 | 149.65 | 217.05 | 252.56 | 332.05 | 97.79 | Upgrade
|
Tangible Book Value Per Share | 1.86 | 2.45 | 3.77 | 5.45 | 7.26 | 4.23 | Upgrade
|
Machinery | - | 40 | 37.63 | 31.82 | 32.79 | 27.59 | Upgrade
|
Construction In Progress | - | 0.5 | 1.69 | 0.51 | 1.08 | - | Upgrade
|
Leasehold Improvements | - | 23.61 | 23.22 | 23.65 | 15.9 | 15.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.